Bepridil exhibits anti ‐leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia

In conclusion, we report in vitro and in vivo anti‐leukemic activity of bepridil associated with inhibition of the NOTCH1 pathway in CLL. These data provide a rationale for the clinical development of bepridil as anti‐NOTCH1 targeted therapy for CLL patients. This article is protected by copyright. All rights reserved.

Source: International Journal of Cancer - March 6, 2018 Category: Cancer & Oncology Authors: Stefano Baldoni, Beatrice Del Papa, Erica Dorillo, Patrizia Aureli, Filomena De Falco, Chiara Rompietti, Daniele Sorcini, Emanuela Varasano, Cecchini Debora, Tiziana Zei, Ambra Di Tommaso, Emanuela Rosati, Gabriela Alexe, Giovanni Roti, Kimberly Stegmaier Tags: Research Article Source Type: research